Accepted for Publication: December 3, 2010.
Author Contributions:Study concept and design: Villemagne, Kung, Skovronsky, and Rowe. Acquisition of data: Villemagne, Pejoska, Drago, Mulligan, Ackermann, O’Keefe, Gong, Tochon-Danguy, Jones, and Rowe. Analysis and interpretation of data: Villemagne, Okamura, Chételat, Masters, and Rowe. Drafting of the manuscript: Villemagne, Skovronsky, Masters, and Rowe. Critical revision of the manuscript for important intellectual content: Villemagne, Skovronsky, Masters, and Rowe. Statistical analysis: Villemagne. Study supervision: Villemagne, Pejoska, and Rowe.
Financial Disclosure: Dr Kung is the chairman of the Scientific Advisory Board for Avid Radiopharmaceuticals Inc, and Dr Skovronsky is president and chief executive officer of Avid Radiopharmaceuticals Inc and, as such, have a financial interest in [18F]AV-133.
Funding/Support: This study was supported in part by funds from Avid Radiopharmaceuticals Inc and the Austin Hospital Medical Research Foundation.